To this date, targeting t(11;14) or high Bcl2 expression using venetoclax is the most clear example of the target therapy principle in MM, and the worse outcomes in unselected population treated with venetoclax further highlight the selective activity of these targeted agents. Here, BCL2 is linked to Miyoshi myopathy.